Sign In
Buy CORT
$72.65
+1.45 (+2.04%)
At Close: Jun 03, 2026
SAN FRANCISCO, March 31, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) that the deadline to move for
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit
05:15pm, Tuesday, 31'st Mar 2026
NEW YORK, March 31, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between Octob
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ:
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of sto
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
12:00pm, Tuesday, 31'st Mar 2026
LOS ANGELES, March 31, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Corcept Th
NEW YORK, March 31, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT). Shareholders who purchased shares of CORT d
NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between Octo
Corcept Gains FDA Approval In Ovarian Cancer (Rating Upgrade)
04:20pm, Monday, 30'th Mar 2026
Corcept Therapeutics Incorporated receives early FDA approval for Lifyorli (relacorilant) in platinum-resistant ovarian cancer, transforming its investment narrative. Lifyorli demonstrated a 35% reduc
Lawsuit Alleges Management Concealed Repeated FDA Warnings Regarding Insufficient Data While Touting Pipeline Readiness; Firm Reminds Investors of April 21 Deadline SAN FRANCISCO, March 30, 2026 /PRNe
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
11:30am, Monday, 30'th Mar 2026
LOS ANGELES, March 30, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Corcept Therapeutics Incorporat
Portnoy Law Firm Announces Class Action on Behalf of Corcept Therapeutics Incorporated Investors
09:00am, Monday, 30'th Mar 2026
LOS ANGELES, March 30, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Corcept Therapeutics Incorporated, (“Corcept” or the "Company") (NASDAQ: CORT) investors of a class action on behalf of
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
04:10am, Monday, 30'th Mar 2026
LOS ANGELES, March 30, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated ("
Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT
04:09am, Monday, 30'th Mar 2026
LOS ANGELES, March 30, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT) for viol
NEW YORK, March 29, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between Octo
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
02:45pm, Saturday, 28'th Mar 2026
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
